Finished product reference
Insulin Biphasic Isophane
Injection · Parenteral · 70 %/30 % · 10 mL
- List code
- 1544
- Pharmacologic class
- Antidiabetic: premixed human insulin (soluble insulin with isophane insulin)
What it is and how it works
A fixed mixture of soluble (regular) human insulin and isophane (NPH) human insulin, commonly 30/70. The soluble fraction provides onset within about 30 minutes, while the isophane fraction gives intermediate-acting basal cover; insulin lowers blood glucose by promoting peripheral glucose uptake and inhibiting hepatic glucose production and lipolysis.
Indications
Treatment of diabetes mellitus requiring insulin.
Dosage and administration (summary)
Subcutaneous injection usually once or twice daily, about 30 minutes before a meal; dose individualised according to blood glucose monitoring. Resuspend by gentle rolling and inversion before use; not for intravenous use.
Contraindications
Hypoglycaemia; hypersensitivity to human insulin or excipients.
Warnings and precautions
Hypoglycaemia is the main risk, especially with missed meals, exercise, alcohol or renal impairment. Rotate injection sites to avoid lipodystrophy and cutaneous amyloidosis; transfer between insulin types or brands requires medical supervision. Combination with thiazolidinediones may cause fluid retention and heart failure.
Pregnancy
Insulin is the treatment of choice in pregnancy; requirements change through pregnancy and need close monitoring.
Storage and supply
Store unopened at 2–8 °C; do not freeze. In use, keep below 25–30 °C for up to 4–6 weeks according to the product; protect from light.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Other presentations of the same active ingredient
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.